तुलना करने के लिए मीट्रिक्स | CYTK | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCYTKपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −9.2x | −1.8x | −0.2x | |
PEG अनुपात | −1.94 | −0.10 | 0.00 | |
क़ीमत/बुक | −22.3x | −1.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 63.3x | 67.6x | 2.7x | |
अपसाइड (विश्लेषक लक्ष्य) | 112.9% | 326.5% | 72.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.1% | 12.4% | अनलॉक करें |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.